Clinical characteristics and follow-up of 60 patients with recent diagnosis of giant cell arteritis, NEWTON study
The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. Our objective is to describe the characteristics and followup of patients with recent diagnosis of GCA in current care. The NEWTON cohort is a monocentric retrospective cohort based...
Gespeichert in:
| Veröffentlicht in: | La revue de medecine interne 2024-06, Vol.45 (6), p.335-342 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 342 |
|---|---|
| container_issue | 6 |
| container_start_page | 335 |
| container_title | La revue de medecine interne |
| container_volume | 45 |
| creator | Goncalves, L Tran, V-T Chauffier, J Bourdin, V Nassarmadji, K Vanjak, A Bigot, W Burlacu, R Champion, K Lopes, A Depont, A Borrero, B A Mangin, O Adle-Biassette, H Bonnin, P Boutigny, A Bonnin, S Neumann, L Mouly, S Sène, D Comarmond, C |
| description | The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. Our objective is to describe the characteristics and followup of patients with recent diagnosis of GCA in current care.
The NEWTON cohort is a monocentric retrospective cohort based on data collected from 60 GCA patients diagnosed between 2017 and 2022 according to the ACR/EULAR 2022 criteria.
The median age at diagnosis was 73 [68.75; 81] years old. At diagnosis, the main manifestations were unusual temporal headaches in 48 (80 %) and an inflammatory syndrome in 50 (83 %) patients. Temporal artery biopsy confirmed the diagnosis in 49/58 (84 %) patients. Doppler of the temporal arteries found a halo in 12/23 (52 %) patients. The PET/CT found hypermetabolism in 19/43 (44 %) patients. Prednisone was stopped in 17.5 [12.75; 24.25] months. During follow-up, 22 (37 %) patients received TCZ. At least one complication of corticosteroid therapy was observed in 22 (37 %) patients. After a median follow-up of 24 [12; 42] months, 25 (42 %) patients relapsed. At the end of the follow-up, 29 (48.3 %) patients were weaned from corticosteroid therapy and 15 (25 %) were on TCZ.
Despite the increasing use of TCZ in the therapeutic arsenal and of the PET/CT in the imaging tools of GCA patients, relapses and complications of corticosteroid therapy remain frequent, observed in more than a third of patients. |
| doi_str_mv | 10.1016/j.revmed.2023.12.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2929033668</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2929033668</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-572bcbadf3807817ea79215cbf8d5403032ea9c658ef9a5c32089d418f1fca033</originalsourceid><addsrcrecordid>eNo10MtKw0AUBuBBEFurbyAySxcmzqVJZpZS6gWk3VRchpO5tFPSJM5MLH0bn8UnM8W6OpzDx8_hR-iGkpQSmj9sU2--dkanjDCeUpYSkp2hMS1ykXDK2AhdhrAlhAxaXqARF4zmXJIx8rPaNU5BjdUGPKhovAvRqYCh0di2dd3uk77DrcU5-fnuIDrTxID3Lm6wN2pYsHawbtrgwlGtHQwnZeoagz-mRRfu8WL-sVoucIi9Plyhcwt1MNenOUHvT_PV7CV5Wz6_zh7fko5RGpOsYJWqQFsuSCFoYaCQjGaqskJnU8IJZwakyjNhrIRMcUaE1FMqLLUKCOcTdPeX2_n2szchljsXjo9BY9o-lEwyObA8FwO9PdG-GmosO-924A_lf0_8F-Jfa6I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2929033668</pqid></control><display><type>article</type><title>Clinical characteristics and follow-up of 60 patients with recent diagnosis of giant cell arteritis, NEWTON study</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Goncalves, L ; Tran, V-T ; Chauffier, J ; Bourdin, V ; Nassarmadji, K ; Vanjak, A ; Bigot, W ; Burlacu, R ; Champion, K ; Lopes, A ; Depont, A ; Borrero, B A ; Mangin, O ; Adle-Biassette, H ; Bonnin, P ; Boutigny, A ; Bonnin, S ; Neumann, L ; Mouly, S ; Sène, D ; Comarmond, C</creator><creatorcontrib>Goncalves, L ; Tran, V-T ; Chauffier, J ; Bourdin, V ; Nassarmadji, K ; Vanjak, A ; Bigot, W ; Burlacu, R ; Champion, K ; Lopes, A ; Depont, A ; Borrero, B A ; Mangin, O ; Adle-Biassette, H ; Bonnin, P ; Boutigny, A ; Bonnin, S ; Neumann, L ; Mouly, S ; Sène, D ; Comarmond, C</creatorcontrib><description>The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. Our objective is to describe the characteristics and followup of patients with recent diagnosis of GCA in current care.
The NEWTON cohort is a monocentric retrospective cohort based on data collected from 60 GCA patients diagnosed between 2017 and 2022 according to the ACR/EULAR 2022 criteria.
The median age at diagnosis was 73 [68.75; 81] years old. At diagnosis, the main manifestations were unusual temporal headaches in 48 (80 %) and an inflammatory syndrome in 50 (83 %) patients. Temporal artery biopsy confirmed the diagnosis in 49/58 (84 %) patients. Doppler of the temporal arteries found a halo in 12/23 (52 %) patients. The PET/CT found hypermetabolism in 19/43 (44 %) patients. Prednisone was stopped in 17.5 [12.75; 24.25] months. During follow-up, 22 (37 %) patients received TCZ. At least one complication of corticosteroid therapy was observed in 22 (37 %) patients. After a median follow-up of 24 [12; 42] months, 25 (42 %) patients relapsed. At the end of the follow-up, 29 (48.3 %) patients were weaned from corticosteroid therapy and 15 (25 %) were on TCZ.
Despite the increasing use of TCZ in the therapeutic arsenal and of the PET/CT in the imaging tools of GCA patients, relapses and complications of corticosteroid therapy remain frequent, observed in more than a third of patients.</description><identifier>EISSN: 1768-3122</identifier><identifier>DOI: 10.1016/j.revmed.2023.12.005</identifier><identifier>PMID: 38216390</identifier><language>fre</language><publisher>France</publisher><ispartof>La revue de medecine interne, 2024-06, Vol.45 (6), p.335-342</ispartof><rights>Copyright © 2023 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38216390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goncalves, L</creatorcontrib><creatorcontrib>Tran, V-T</creatorcontrib><creatorcontrib>Chauffier, J</creatorcontrib><creatorcontrib>Bourdin, V</creatorcontrib><creatorcontrib>Nassarmadji, K</creatorcontrib><creatorcontrib>Vanjak, A</creatorcontrib><creatorcontrib>Bigot, W</creatorcontrib><creatorcontrib>Burlacu, R</creatorcontrib><creatorcontrib>Champion, K</creatorcontrib><creatorcontrib>Lopes, A</creatorcontrib><creatorcontrib>Depont, A</creatorcontrib><creatorcontrib>Borrero, B A</creatorcontrib><creatorcontrib>Mangin, O</creatorcontrib><creatorcontrib>Adle-Biassette, H</creatorcontrib><creatorcontrib>Bonnin, P</creatorcontrib><creatorcontrib>Boutigny, A</creatorcontrib><creatorcontrib>Bonnin, S</creatorcontrib><creatorcontrib>Neumann, L</creatorcontrib><creatorcontrib>Mouly, S</creatorcontrib><creatorcontrib>Sène, D</creatorcontrib><creatorcontrib>Comarmond, C</creatorcontrib><title>Clinical characteristics and follow-up of 60 patients with recent diagnosis of giant cell arteritis, NEWTON study</title><title>La revue de medecine interne</title><addtitle>Rev Med Interne</addtitle><description>The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. Our objective is to describe the characteristics and followup of patients with recent diagnosis of GCA in current care.
The NEWTON cohort is a monocentric retrospective cohort based on data collected from 60 GCA patients diagnosed between 2017 and 2022 according to the ACR/EULAR 2022 criteria.
The median age at diagnosis was 73 [68.75; 81] years old. At diagnosis, the main manifestations were unusual temporal headaches in 48 (80 %) and an inflammatory syndrome in 50 (83 %) patients. Temporal artery biopsy confirmed the diagnosis in 49/58 (84 %) patients. Doppler of the temporal arteries found a halo in 12/23 (52 %) patients. The PET/CT found hypermetabolism in 19/43 (44 %) patients. Prednisone was stopped in 17.5 [12.75; 24.25] months. During follow-up, 22 (37 %) patients received TCZ. At least one complication of corticosteroid therapy was observed in 22 (37 %) patients. After a median follow-up of 24 [12; 42] months, 25 (42 %) patients relapsed. At the end of the follow-up, 29 (48.3 %) patients were weaned from corticosteroid therapy and 15 (25 %) were on TCZ.
Despite the increasing use of TCZ in the therapeutic arsenal and of the PET/CT in the imaging tools of GCA patients, relapses and complications of corticosteroid therapy remain frequent, observed in more than a third of patients.</description><issn>1768-3122</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo10MtKw0AUBuBBEFurbyAySxcmzqVJZpZS6gWk3VRchpO5tFPSJM5MLH0bn8UnM8W6OpzDx8_hR-iGkpQSmj9sU2--dkanjDCeUpYSkp2hMS1ykXDK2AhdhrAlhAxaXqARF4zmXJIx8rPaNU5BjdUGPKhovAvRqYCh0di2dd3uk77DrcU5-fnuIDrTxID3Lm6wN2pYsHawbtrgwlGtHQwnZeoagz-mRRfu8WL-sVoucIi9Plyhcwt1MNenOUHvT_PV7CV5Wz6_zh7fko5RGpOsYJWqQFsuSCFoYaCQjGaqskJnU8IJZwakyjNhrIRMcUaE1FMqLLUKCOcTdPeX2_n2szchljsXjo9BY9o-lEwyObA8FwO9PdG-GmosO-924A_lf0_8F-Jfa6I</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Goncalves, L</creator><creator>Tran, V-T</creator><creator>Chauffier, J</creator><creator>Bourdin, V</creator><creator>Nassarmadji, K</creator><creator>Vanjak, A</creator><creator>Bigot, W</creator><creator>Burlacu, R</creator><creator>Champion, K</creator><creator>Lopes, A</creator><creator>Depont, A</creator><creator>Borrero, B A</creator><creator>Mangin, O</creator><creator>Adle-Biassette, H</creator><creator>Bonnin, P</creator><creator>Boutigny, A</creator><creator>Bonnin, S</creator><creator>Neumann, L</creator><creator>Mouly, S</creator><creator>Sène, D</creator><creator>Comarmond, C</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20240601</creationdate><title>Clinical characteristics and follow-up of 60 patients with recent diagnosis of giant cell arteritis, NEWTON study</title><author>Goncalves, L ; Tran, V-T ; Chauffier, J ; Bourdin, V ; Nassarmadji, K ; Vanjak, A ; Bigot, W ; Burlacu, R ; Champion, K ; Lopes, A ; Depont, A ; Borrero, B A ; Mangin, O ; Adle-Biassette, H ; Bonnin, P ; Boutigny, A ; Bonnin, S ; Neumann, L ; Mouly, S ; Sène, D ; Comarmond, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-572bcbadf3807817ea79215cbf8d5403032ea9c658ef9a5c32089d418f1fca033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goncalves, L</creatorcontrib><creatorcontrib>Tran, V-T</creatorcontrib><creatorcontrib>Chauffier, J</creatorcontrib><creatorcontrib>Bourdin, V</creatorcontrib><creatorcontrib>Nassarmadji, K</creatorcontrib><creatorcontrib>Vanjak, A</creatorcontrib><creatorcontrib>Bigot, W</creatorcontrib><creatorcontrib>Burlacu, R</creatorcontrib><creatorcontrib>Champion, K</creatorcontrib><creatorcontrib>Lopes, A</creatorcontrib><creatorcontrib>Depont, A</creatorcontrib><creatorcontrib>Borrero, B A</creatorcontrib><creatorcontrib>Mangin, O</creatorcontrib><creatorcontrib>Adle-Biassette, H</creatorcontrib><creatorcontrib>Bonnin, P</creatorcontrib><creatorcontrib>Boutigny, A</creatorcontrib><creatorcontrib>Bonnin, S</creatorcontrib><creatorcontrib>Neumann, L</creatorcontrib><creatorcontrib>Mouly, S</creatorcontrib><creatorcontrib>Sène, D</creatorcontrib><creatorcontrib>Comarmond, C</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>La revue de medecine interne</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goncalves, L</au><au>Tran, V-T</au><au>Chauffier, J</au><au>Bourdin, V</au><au>Nassarmadji, K</au><au>Vanjak, A</au><au>Bigot, W</au><au>Burlacu, R</au><au>Champion, K</au><au>Lopes, A</au><au>Depont, A</au><au>Borrero, B A</au><au>Mangin, O</au><au>Adle-Biassette, H</au><au>Bonnin, P</au><au>Boutigny, A</au><au>Bonnin, S</au><au>Neumann, L</au><au>Mouly, S</au><au>Sène, D</au><au>Comarmond, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical characteristics and follow-up of 60 patients with recent diagnosis of giant cell arteritis, NEWTON study</atitle><jtitle>La revue de medecine interne</jtitle><addtitle>Rev Med Interne</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>45</volume><issue>6</issue><spage>335</spage><epage>342</epage><pages>335-342</pages><eissn>1768-3122</eissn><abstract>The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. Our objective is to describe the characteristics and followup of patients with recent diagnosis of GCA in current care.
The NEWTON cohort is a monocentric retrospective cohort based on data collected from 60 GCA patients diagnosed between 2017 and 2022 according to the ACR/EULAR 2022 criteria.
The median age at diagnosis was 73 [68.75; 81] years old. At diagnosis, the main manifestations were unusual temporal headaches in 48 (80 %) and an inflammatory syndrome in 50 (83 %) patients. Temporal artery biopsy confirmed the diagnosis in 49/58 (84 %) patients. Doppler of the temporal arteries found a halo in 12/23 (52 %) patients. The PET/CT found hypermetabolism in 19/43 (44 %) patients. Prednisone was stopped in 17.5 [12.75; 24.25] months. During follow-up, 22 (37 %) patients received TCZ. At least one complication of corticosteroid therapy was observed in 22 (37 %) patients. After a median follow-up of 24 [12; 42] months, 25 (42 %) patients relapsed. At the end of the follow-up, 29 (48.3 %) patients were weaned from corticosteroid therapy and 15 (25 %) were on TCZ.
Despite the increasing use of TCZ in the therapeutic arsenal and of the PET/CT in the imaging tools of GCA patients, relapses and complications of corticosteroid therapy remain frequent, observed in more than a third of patients.</abstract><cop>France</cop><pmid>38216390</pmid><doi>10.1016/j.revmed.2023.12.005</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1768-3122 |
| ispartof | La revue de medecine interne, 2024-06, Vol.45 (6), p.335-342 |
| issn | 1768-3122 |
| language | fre |
| recordid | cdi_proquest_miscellaneous_2929033668 |
| source | Elsevier ScienceDirect Journals Complete |
| title | Clinical characteristics and follow-up of 60 patients with recent diagnosis of giant cell arteritis, NEWTON study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T14%3A46%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20characteristics%20and%20follow-up%20of%2060%C2%A0patients%20with%20recent%20diagnosis%20of%20giant%20cell%20arteritis,%20NEWTON%20study&rft.jtitle=La%20revue%20de%20medecine%20interne&rft.au=Goncalves,%20L&rft.date=2024-06-01&rft.volume=45&rft.issue=6&rft.spage=335&rft.epage=342&rft.pages=335-342&rft.eissn=1768-3122&rft_id=info:doi/10.1016/j.revmed.2023.12.005&rft_dat=%3Cproquest_pubme%3E2929033668%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2929033668&rft_id=info:pmid/38216390&rfr_iscdi=true |